Analyzing Kezar Life Sciences (NASDAQ:KZR) & Enlivex Therapeutics (NASDAQ:ENLV)

Kezar Life Sciences (NASDAQ:KZR) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Earnings & Valuation

This table compares Kezar Life Sciences and Enlivex Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kezar Life Sciences	$7.00 million	4.96	-$101.87 million	($11.55)	-0.41
Enlivex Therapeutics	N/A	N/A	-$29.07 million	($0.73)	-1.32

Enlivex Therapeutics has lower revenue, but higher earnings than Kezar Life Sciences. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Kezar Life Sciences has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Kezar Life Sciences and Enlivex Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kezar Life Sciences	0	2	1	0	2.33
Enlivex Therapeutics	0	0	2	1	3.33

Kezar Life Sciences presently has a consensus price target of $39.50, indicating a potential upside of 731.58%. Enlivex Therapeutics has a consensus price target of $10.00, indicating a potential upside of 941.67%. Given Enlivex Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Kezar Life Sciences.

Profitability

This table compares Kezar Life Sciences and Enlivex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kezar Life Sciences	N/A	-54.95%	-46.11%
Enlivex Therapeutics	N/A	-67.57%	-58.45%

Insider and Institutional Ownership

67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 9.3% of Kezar Life Sciences shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Enlivex Therapeutics beats Kezar Life Sciences on 8 of the 13 factors compared between the two stocks.

About Kezar Life Sciences

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.